Ambit Biosciences Corporation AMBI saw a big move last session, as the company's shares fell by over 13% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This continues the recent downtrend for AMBI, as the stock is now down nearly 36% since Mar 19.
This slump shouldn't be too much of a surprise to investors, as this biopharmaceutical company has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
AMBI currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked stocks in the same sector include Amgen Inc. AMGN, Myriad Genetics Inc. MYGN and Regeneron Pharmaceuticals, Inc. REGN. All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
This slump shouldn't be too much of a surprise to investors, as this biopharmaceutical company has seen 1 negative revision in the past few weeks and its current year earnings consensus has moved lower over the last 30 days. This suggests there may be more trouble down the road. So make sure to keep an eye on this stock going forward to see if this recent slump will continue, as the earnings picture definitely suggests that this might be the case.
AMBI currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.
Some better-ranked stocks in the same sector include Amgen Inc. AMGN, Myriad Genetics Inc. MYGN and Regeneron Pharmaceuticals, Inc. REGN. All these stocks sport a Zacks Rank #1 (Strong Buy).
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
AMBIT BIOSCIENC AMBI: Free Stock Analysis Report
AMGEN INC AMGN: Free Stock Analysis Report
MYRIAD GENETICS MYGN: Free Stock Analysis Report
REGENERON PHARM REGN: Free Stock Analysis Report
To read this article on Zacks.com click here.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
